CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Emergence of Biosimilars
4.1.2. Increasing prevalence of chronic diseases and lifestyle disorders
4.1.3. Growing demand for monoclonal antibodies
4.1.4. The high adoption rate of targeted therapy over traditional therapies
4.2. Market Restraints & Challenges
4.2.1. The high cost of immunotherapy treatment
4.2.2. High reduction rate in the product development cycle
4.3. Market Opportunities
4.3.1. Emerging markets
4.3.2. Immunotherapy to replace chemotherapy in cancer treatment
CHAPTER 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET – BY DRUG TYPE
5.1. Monoclonal Antibodies
5.2. Adult Vaccines
5.2.1. Preventive Vaccines
5.2.2. Therapeutic Vaccines
5.3. Checkpoint Inhibitors
5.4. Interferons Alpha & Beta
5.5. Interleukins
5.6. Others
CHAPTER 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET – BY THERAPY
AREA
6.1. Cancer
6.2. Autoimmune and Inflammatory Diseases
6.3. Infectious Diseases
6.4. Others
CHAPTER 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET – BY END USER
7.1. Cancer Research Centers
7.2. Hospitals/Clinics
7.3. Others
CHAPTER 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET - COMPANY
PROFILES
9.1. AbbVie Inc.
9.2. Amgen Inc.
9.3. AstraZeneca PLC
9.4. Bristol-Myers Squibb
9.5. F-Hoffman-La Roche AG
9.6. Johnson & Johnson
9.7. Novartis International AG
9.8. GlaxoSmithKline PLC
9.9. UbiVac
9.10. Eli Lilly and Company
9.11. Merck & Co., Inc.
9.12. Alligator Bioscience
9.13. Incyte Corporation
9.14. Celldex Therapeutics
9.15. Intrexon Corporation
CHAPTER 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures